title: Establishment and characterization of a new mantle cell lymphoma cell line M-1.
abstract: A new mantle cell lymphoma cell line, M-1, was established from peripheral blood mononuclear cells of a patient with a diagnosis of blastoid variant of mantle cell lymphoma in leukemic phase. This cell line showed cell surface antigens identical to the original tumor and demonstrated the profile of a mature B-cell phenotype typical of mantle cell lymphoma: positive for CD5, CD19, CD20, sIgM and FMC7, and negative for CD3, CD10 and CD23. Cytogenetically, the M-1 cell line showed chromosomal alterations similar to the initial clinical specimen, among which a translocation t(11;14) (q13;q32) resulting in the overexpression of cyclin D1 as well as additional abnormalities involving chromosomes 3, 9 and 10. This cell line was used as a model to investigate the activity of the three drugs doxorubicin, cyclophosphamide and vincristine, commonly used in the treatment of mantle cell lymphoma patients. The effect of the drugs was evaluated by a 24 h cytotoxicity test and a 7-days anti-proliferation test using a microculture tetrazolium-based assay (MTT). Both assays indicated a higher sensitivity of the cell line to vincristine when compared to doxorubicin and cyclophosphamide. The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas 77030, USA. ahgoy@mail.mdanderson.org
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
authors.forename: Yvonne K
authors.initials: YK
authors.lastname: Remache
authors.forename: Jun
authors.initials: J
authors.lastname: Gu
authors.forename: John
authors.initials: J
authors.lastname: Stewart
authors.forename: Kimberly J
authors.initials: KJ
authors.lastname: Hayes
authors.forename: David
authors.initials: D
authors.lastname: Gold
authors.forename: Yunfang
authors.initials: Y
authors.lastname: Jiang
authors.forename: Bedia A
authors.initials: BA
authors.lastname: Barkoh
authors.forename: Ruth
authors.initials: R
authors.lastname: Katz
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabanillas
authors.forename: Frederic
authors.initials: F
authors.lastname: Gilles
mesh_terms: D000954:Antigens, Surface / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D019938:Cyclin D1 / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D016130:Immunophenotyping; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014750:Vincristine / Q000494:pharmacology
chemical_list: D000954:Antigens, Surface; D000970:Antineoplastic Agents; D019938:Cyclin D1; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide